172. Hepatitis and Liver Disease in HIV Patients
Friday, October 28, 2016: 2:00 PM-3:30 PM
Room: Theater C

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • evaluate treatment options for patients co-infected with HIV and HCV
  • manage the treatment of patients co-infected with hepatitis B and HIV infection
  • recognize and respond to fatty liver disease in patients with HIV

Target Audience: Clinicians, Fellows, HIV clinicians, HIV specialists, Infectious diseases physicians, Public health practitioners

Tracks: Adult ID, HIV-STD-TB

Moderators:  Pablo Tebas, MD, FIDSA, University of Pennsylvania and Daniel Fierer, MD, FIDSA, Icahn School of Medicine at Mount Sinai

2:25 PM
2:30 PM
Hepatitis B in HIV Patients
Oluwatoyin Adeyemi, MD

2:55 PM
3:25 PM

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours .15 of pharmacy CE

ACPE Number: 0221-9999-16-270-L02-P


P. Tebas, Merck: Consultant , Consulting fee
Glaxo: Adjudication Committe member , Consulting fee

D. Fierer, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.